-PDF Download- Innovation In Drug Research And Development For Prevalent Chronic Diseases EBOOK

Innovation in Drug Research and Development for Prevalent Chronic Diseases

Author:

Publisher:

Published: 2021

Total Pages: 96

ISBN-13:

Investment and innovation in drug research and development (R&D) for highly prevalent chronic diseases has stalled in recent decades, despite half of all Americans living with at least one chronic disease. As a result, prevalent chronic diseases are producing immense health care costs as well as preventable suffering and death. On February 22, March 2, and March 8, 2021, the National Academies of Sciences, Engineering, and Medicine, convened a workshop to discuss barriers to innovation in this space and examine strategies and incentives to support equitable, person-centered drug R&D for prevalent chronic diseases.

The Role of NIH in Drug Development Innovation and Its Impact on Patient Access

Author: National Academies of Sciences, Engineering, and Medicine

Publisher: National Academies Press

Published: 2020-01-27

Total Pages: 103

ISBN-13: 0309498511

DOWNLOAD EBOOK →

To explore the role of the National Institutes of Health (NIH) in innovative drug development and its impact on patient access, the Board on Health Care Services and the Board on Health Sciences Policy of the National Academies jointly hosted a public workshop on July 24â€"25, 2019, in Washington, DC. Workshop speakers and participants discussed the ways in which federal investments in biomedical research are translated into innovative therapies and considered approaches to ensure that the public has affordable access to the resulting new drugs. This publication summarizes the presentations and discussions from the workshop.

Breakthrough Business Models

Author: Institute of Medicine

Publisher: National Academies Press

Published: 2009-02-17

Total Pages: 151

ISBN-13: 0309178169

DOWNLOAD EBOOK →

The process for developing new drug and biologic products is extraordinarily expensive and time-consuming. Although large pharmaceutical companies may be able to afford the cost of development because they can expect a large return on investment, organizations developing drugs to treat rare and neglected diseases are unable to rely on such returns. On June 23, 2008, the Institute of Medicine's Forum on Drug Discovery, Development, and Translation held a public workshop, "Breakthrough Business Models: Drug Development for Rare and Neglected Diseases and Individualized Therapies," which sought to explore new and innovative strategies for developing drugs for rare and neglected diseases.

Rare Diseases and Orphan Products

Author: Institute of Medicine

Publisher: National Academies Press

Published: 2011-04-03

Total Pages: 442

ISBN-13: 0309158060

DOWNLOAD EBOOK →

Rare diseases collectively affect millions of Americans of all ages, but developing drugs and medical devices to prevent, diagnose, and treat these conditions is challenging. The Institute of Medicine (IOM) recommends implementing an integrated national strategy to promote rare diseases research and product development.

Pharmaceutical Innovation

Author: Ralph Landau

Publisher: Chemical Heritage Foundation

Published: 1999

Total Pages: 442

ISBN-13: 9780941901215

DOWNLOAD EBOOK →

Documents how science has provided an astonishing array of medicines for coping with human ailments. This volume addresses industry leaders, economic influences, and the development of individual products. It is suitable for policy makers, economists, corporate executives, research managers, and historians of science, technology, and medicine.

Accelerating the Development of New Drugs and Diagnostics

Author: Institute of Medicine

Publisher: National Academies Press

Published: 2012-10-23

Total Pages: 108

ISBN-13: 0309261198

DOWNLOAD EBOOK →

Advances in technologies and knowledge are creating new avenues for research and opportunities for the discovery and clinical development of innovative therapies and diagnostics. However, despite these opportunities, only a small fraction of investigational products are successfully developed into cures and therapies that can be accessed by patients. One response to the ever-widening gap between the number and promise of basic scientific discoveries and the translation of those discoveries into therapies is a renewed emphasis on collaborative approaches among federal agencies, academia, and industry, all directed at the advancement of the drug development enterprise. The newly developed Cures Acceleration Network (CAN)-a part of the National Center for Advancing Translational Sciences (NCATS) within the National Institutes of Health (NIH)-has the potential to catalyze widespread changes in NCATS, NIH, and the drug development ecosystem in general. On June 4-5, 2012, the IOM Forum on Drug Discovery, Development, and Translation held, at the request of NCATS, a workshop-bringing together members of federal government agencies, the private sector, academia, and advocacy groups-to explore options and opportunities in the implementation of CAN. Accelerating the Development of New Drugs and Diagnostics: Maximizing the Impact of the Cures Acceleration Network: Workshop Summary summarizes the workshop.

Technological Innovation

Author: Annetine C. Gelijns

Publisher: National Academies

Published: 1989

Total Pages: 78

ISBN-13:

DOWNLOAD EBOOK →

Research and Development in the Pharmaceutical Industry (A CBO Study)

Author: Congressional Budget Office

Publisher: Lulu.com

Published: 2013-06-09

Total Pages: 65

ISBN-13: 1304121445

DOWNLOAD EBOOK →

Perceptions that the pace of new-drug development has slowed and that the pharmaceutical industry is highly profitable have sparked concerns that significant problems loom for future drug development. This Congressional Budget Office (CBO) study-prepared at the request of the Senate Majority Leader-reviews basic facts about the drug industry's recent spending on research and development (R&D) and its output of new drugs. The study also examines issues relating to the costs of R&D, the federal government's role in pharmaceutical research, the performance of the pharmaceutical industry in developing innovative drugs, and the role of expected profits in private firms' decisions about investing in drug R&D. In keeping with CBO's mandate to provide objective, impartial analysis, the study makes no recommendations. David H. Austin prepared this report under the supervision of Joseph Kile and David Moore. Colin Baker provided valuable consultation...

The Science of Medicines Exploring Drug Discovery and Development

Author: Derek Otto

Publisher:

Published: 2023-12-03

Total Pages: 0

ISBN-13:

DOWNLOAD EBOOK →

The Importance of MedicinesIn today's fast-paced world, medicines play a vital role in maintaining and improving our overall health. From curing life-threatening diseases to alleviating common ailments, the significance of medicines cannot be overstated. This subchapter aims to highlight the importance of medicines in our lives and shed light on their role in the field of biomedical science and biotechnology. Medicines are a cornerstone of modern healthcare, enabling us to combat a vast array of illnesses and conditions. They are designed to target specific diseases and provide relief by either eliminating the root cause or managing symptoms. Without medicines, our ability to prevent, treat, and cure diseases would be severely limited. One of the key aspects of medicines is their role in drug discovery and development. Biomedical science and biotechnology rely heavily on the creation and advancement of new drugs to tackle emerging health challenges. Through rigorous research and testing, scientists can develop innovative medicines that address unmet medical needs, saving countless lives in the process. Medicines have revolutionized the treatment of chronic diseases, such as diabetes, hypertension, and asthma. They allow individuals to manage these conditions effectively, leading to improved quality of life and longevity. Additionally, medicines have played a crucial role in eradicating or controlling infectious diseases like smallpox, polio, and tuberculosis, transforming the landscape of public health. In the field of biotechnology, medicines have opened doors to groundbreaking therapies. Biologic drugs, derived from living organisms, have revolutionized the treatment of diseases like cancer, rheumatoid arthritis, and multiple sclerosis. These innovative medicines offer targeted treatments, minimizing side effects and maximizing efficacy. Furthermore, medicines have a significant impact on society as a whole. They not only alleviate human suffering but also contribute to economic development. By improving health outcomes, medicines enable individuals to live productive lives, contributing to the growth of communities and nations. Moreover, the pharmaceutical industry generates employment opportunities, drives research and innovation, and fosters collaborations across various scientific disciplines.

Global Health and the Future Role of the United States

Author: National Academies of Sciences, Engineering, and Medicine

Publisher: National Academies Press

Published: 2017-10-05

Total Pages: 385

ISBN-13: 0309457637

DOWNLOAD EBOOK →

While much progress has been made on achieving the Millenium Development Goals over the last decade, the number and complexity of global health challenges has persisted. Growing forces for globalization have increased the interconnectedness of the world and our interdependency on other countries, economies, and cultures. Monumental growth in international travel and trade have brought improved access to goods and services for many, but also carry ongoing and ever-present threats of zoonotic spillover and infectious disease outbreaks that threaten all. Global Health and the Future Role of the United States identifies global health priorities in light of current and emerging world threats. This report assesses the current global health landscape and how challenges, actions, and players have evolved over the last decade across a wide range of issues, and provides recommendations on how to increase responsiveness, coordination, and efficiency â€" both within the U.S. government and across the global health field.